CD ComputaBio provides Molecular Docking for SAR Interpretation Service to help medicinal chemists and computational biologists decode how ligand binding modes drive biological activity across compound series. By integrating molecular docking, interaction fingerprint profiling, conformational ensemble analysis, pharmacophore mapping, and binding energy decomposition, our scientists transform docking outputs into clear SAR narratives that directly inform lead optimization, scaffold hopping, selectivity engineering, and intellectual property strategy.
We dock each compound in your congeneric series into the target-binding site using multiple docking engines with consensus scoring, then align poses to extract conserved versus divergent interaction patterns that explain potency and selectivity variations.
We compute per-ligand interaction fingerprints cataloguing hydrogen bonds (donor/acceptor), salt bridges, π-π stacking, π-cation, hydrophobic contacts, halogen bonds, and water bridges, then cluster compounds by interaction similarity to reveal SAR sub-groups.
We build 3D-QSAR models (CoMFA steric/electrostatic fields, CoMSIA including hydrophobic/H-bond donor/acceptor fields) using docked and aligned poses, generating contour maps that show favorable and unfavorable regions for steric bulk, charge, and hydrogen bonding.
We derive 3D pharmacophore models directly from docked protein-ligand complexes, identifying essential features (H-bond donors/acceptors, hydrophobic regions, aromatic rings, positive/negative ionizable centers) that constitute the minimal binding pharmacophore for activity.
We decompose binding free energies (MM-GBSA/PBSA) at the per-residue level to identify which amino acids contribute most to affinity, revealing hotspot residues that drive SAR and suggesting positions where mutations would affect selectivity across paralogs or orthologs.
We dock compounds into multiple related targets (e.g., kinase panel, GPCR subtypes, CYP isoforms) to compare binding poses and interaction patterns, explaining selectivity cliffs and identifying structural determinants that can be exploited to enhance target selectivity.
We dock ligands against multiple receptor conformations (holo, apo, MD-derived snapshots) to capture protein flexibility effects on SAR, ensuring that conformational selection and induced-fit contributions are not overlooked when rationalizing activity differences across a series.
Multiple scoring functions (GoldScore, ChemScore, ASP, ChemPLP, GlideScore, Vina) are applied in parallel, with consensus ranking used to reduce single-function bias and improve correlation between predicted and experimental binding affinities across a congeneric series.
Post-docking MM-GBSA/PBSA calculations provide physics-based binding free energy estimates with per-residue decomposition, offering better correlation with experimental ΔG than docking scores alone—critical for reliably ranking close analogs in a lead optimization campaign.
For high-value lead optimization decisions, we apply FEP+ to compute relative binding free energies between structurally similar compounds, achieving near-chemical-accuracy ΔΔG predictions that directly inform which R-group modifications are worth synthesizing.
A tiered docking workflow applies high-throughput virtual screening (HTVS) for millions of compounds, followed by standard precision (SP) and extra precision (XP) docking for the top fraction, efficiently balancing speed and accuracy for library-scale SAR exploration.
For covalent inhibitors and fragment-based drug discovery, we employ specialized covalent docking protocols (CovDock, DOCKovalent) and fragment-docking workflows that account for bond-formation geometry and weak-affinity binding modes, respectively.
We review available crystal structures, cryo-EM maps, or homology models of the target; assess binding-site completeness, water networks, cofactors, and post-translational modifications; and define the SAR question the docking analysis should answer.
We prepare all compounds in the series with correct protonation states at physiological pH, enumerate tautomers and stereoisomers, generate ring conformations, minimize 3D structures, and assign partial charges using validated force fields or semi-empirical methods.
We add missing loops and side chains, optimize hydrogen-bond networks, assign protonation states to titratable residues (using PROPKA or H++), resolve crystallographic waters (conserved vs displaceable), and define the docking grid around the co-crystallized ligand or key catalytic residues.
We dock all compounds using selected protocols and validate performance by redocking the co-crystallized ligand (RMSD < 2.0 Å required), then export the best-scoring poses with their interaction profiles for downstream SAR analysis.
We compute interaction fingerprints across the entire series, generate IFP similarity matrices, per-residue contact frequency tables, 2D interaction diagrams, 3D pharmacophore maps, and CoMFA/CoMSIA field contours to extract the 3D SAR story from the docking data.
We synthesize all findings into a comprehensive report: pose comparisons annotated with activity data, interaction heatmaps, residue-level energy decomposition, QSAR contour maps, pharmacophore models, selectivity analysis, and prioritized suggestions for the next round of compound design.
| Research Question | Recommended Docking Approach | Key SAR Outputs | Decision Supported |
|---|---|---|---|
| Why does compound 7 show 50-fold higher potency than compound 3 despite a single methyl difference? | Flexible docking with per-residue energy decomposition and MM-GBSA | Pose overlay showing steric clash relief, new hydrophobic contact formed, ΔG per-residue heatmap | Identify sub-pocket that tolerates substitution; guide R-group exploration at that vector |
| How can I achieve selectivity for kinase A over kinase B? | Cross-target docking in ensemble mode with selectivity-determinant residue mapping | Pairwise pose comparison, differential interaction fingerprint, gatekeeper-residue contact analysis | Design compounds targeting non-conserved residues; selectivity-focused pharmacophore model |
| My scaffold hop lost activity. Does the new core engage the same interactions? | Docking both series, pharmacophore alignment, interaction fingerprint comparison | Tanimoto IFP similarity matrix, pharmacophore overlay, per-feature RMSD of key interactions | Identify missing or suboptimal interactions; suggest core modifications to restore binding |
| Can docking-derived QSAR predict which analogs to synthesize next? | Consensus docking, pose alignment, CoMFA/CoMSIA model building | Steric/electrostatic contour maps, q²/r² validation metrics, predicted pIC₅₀ for virtual compounds | Rank virtual library by predicted activity; select top N compounds for synthesis |
| What is the minimal pharmacophore required for activity? | Docking-based pharmacophore extraction from multiple protein-ligand complexes | 3D pharmacophore model with feature tolerances, exclusion volumes, and feature ranking by frequency | Use pharmacophore for virtual screening, fragment growing, or IP strategy definition |
| Does water-mediated hydrogen bonding explain the SAR discontinuity at position 4? | Water-aware docking (WaterMap, 3D-RISM, or Grid-based) with water network analysis | Displaceable vs structural water classification, WaterMap ΔG for water sites, water-bridge frequency | Decide whether to displace, retain, or target structural waters with functional group design |
When the addition of a single methyl group causes a 100-fold potency shift, docking can reveal whether steric clash, lost hydrogen bond, disrupted water network, or altered conformational preference is responsible—and suggest how to recover activity.
Before investing in a new chemical series, we dock the proposed scaffold into the target and compare its interaction fingerprint with that of the reference series, quantifying whether essential contacts (hinge-region H-bonds, key hydrophobic pockets) are conserved.
By docking compounds into structurally aligned pairs of on-target and off-target proteins, we identify non-conserved residues near the binding site that can be engaged to gain selectivity—and propose specific functional groups to reach those residues.
We extract pharmacophore models from patent-exemplified compounds docked into the target, then use these models to assess whether new chemical matter falls within or outside existing IP claims, supporting design-around strategies for novel composition-of-matter patents.
For prodrug strategies, we dock both the prodrug and the active species to assess whether the promoiety sterically blocks key binding interactions, and model the enzymatic cleavage trajectory to estimate in vivo activation rates in context of the target binding pocket.
When clinical or in vitro resistance mutations emerge, we perform mutation-site docking (in silico mutagenesis + redocking) to predict which mutations would disrupt binding and which compounds in the series might retain activity, informing backup-series selection before resistance appears.
Docking software generates pose files and scores, but converting those outputs into an actionable SAR narrative requires deep experience in medicinal chemistry, structural biology, and computational modeling. CD ComputaBio bridges the gap by combining rigorous docking protocols with expert SAR interpretation that medicinal chemists can act on immediately.
Goal: explain potency differences across a systematically varied R₁/R₂ substitution matrix and prioritize the next library design.
Goal: identify the structural basis of selectivity between closely related protein targets and propose selectivity-enhancing modifications.
Goal: build a robust CoMFA/CoMSIA model from docked poses to predict activity of virtual compounds before synthesis.
Standard virtual screening aims to enrich active compounds from a large library using a single scoring cutoff. Docking for SAR interpretation, in contrast, focuses on a congeneric series of known actives and inactives, emphasizing pose consistency, interaction fingerprint comparison, per-residue energy decomposition, and cross-compound pose alignment to explain relative potency differences—not just rank-ordering.
We can use high-quality homology models built with AlphaFold2, RoseTTAFold, or traditional template-based modeling, validated by Ramachandran analysis and docking enrichment benchmarks. For targets with flexible or disordered binding sites, we combine homology modeling with MD-refined conformational ensembles to improve docking accuracy. We always disclose the limitations of model-based versus crystal-structure-based docking.
We apply multiple validation steps: (1) pose reproduction (redocking the co-crystallized ligand with RMSD < 2.0 Å); (2) binding-mode consistency across analogs (pose clustering by IFP similarity); (3) correlation between docking scores or MM-GBSA ΔG and experimental activity; (4) pose stability in short MD refinement; and (5) agreement with available mutagenesis or SAR data. Poses that fail consistency checks are flagged and discussed.
Yes, but the resolution required depends on the system. Simple scoring-function differences may not reliably capture a 0.5 kcal/mol ΔΔG. In these cases, we escalate to MM-GBSA per-residue decomposition, water network analysis (to check for water displacement), or FEP+ for high-confidence relative free energy predictions. We recommend the appropriate tier of analysis based on the SAR question's difficulty and the decision's importance.
For a focused series of 20-50 compounds with an available crystal structure, a standard docking-SAR analysis (poses + interaction fingerprints + per-residue energy decomposition + 2D diagrams + summary report) typically takes 1-2 weeks. Projects involving ensemble docking, CoMFA/CoMSIA model building, cross-target selectivity profiling, or FEP+ calculations may require 2-4 weeks depending on complexity. Rush options are available; please discuss timelines during project scoping.
Share your compound series, activity data, target structure, and the SAR questions you need answered. Our team will design a docking-based SAR interpretation workflow that delivers clear, decision-ready insights for your next lead optimization or patent strategy decision.
Submit Project DetailsSubmit your project details below, and our team will respond within 24 hours.
Talk to our technical team about your project!
I Want To Talk